JPWO2020118113A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020118113A5 JPWO2020118113A5 JP2021531047A JP2021531047A JPWO2020118113A5 JP WO2020118113 A5 JPWO2020118113 A5 JP WO2020118113A5 JP 2021531047 A JP2021531047 A JP 2021531047A JP 2021531047 A JP2021531047 A JP 2021531047A JP WO2020118113 A5 JPWO2020118113 A5 JP WO2020118113A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- crystalline form
- xrpd
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188449A JP2025026857A (ja) | 2018-12-06 | 2024-10-25 | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018119567 | 2018-12-06 | ||
| CNPCT/CN2018/119567 | 2018-12-06 | ||
| PCT/US2019/064784 WO2020118113A1 (en) | 2018-12-06 | 2019-12-05 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188449A Division JP2025026857A (ja) | 2018-12-06 | 2024-10-25 | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511800A JP2022511800A (ja) | 2022-02-01 |
| JPWO2020118113A5 true JPWO2020118113A5 (https=) | 2022-12-12 |
| JP2022511800A5 JP2022511800A5 (https=) | 2022-12-12 |
Family
ID=70974392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531047A Pending JP2022511800A (ja) | 2018-12-06 | 2019-12-05 | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| JP2024188449A Pending JP2025026857A (ja) | 2018-12-06 | 2024-10-25 | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188449A Pending JP2025026857A (ja) | 2018-12-06 | 2024-10-25 | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12145917B2 (https=) |
| EP (1) | EP3890723A4 (https=) |
| JP (2) | JP2022511800A (https=) |
| KR (1) | KR102946486B1 (https=) |
| CN (1) | CN113226302B (https=) |
| AU (1) | AU2019394974B2 (https=) |
| BR (1) | BR112021010708A2 (https=) |
| EA (1) | EA202191545A1 (https=) |
| IL (1) | IL283663B2 (https=) |
| SG (1) | SG11202105745UA (https=) |
| TW (1) | TWI828817B (https=) |
| WO (1) | WO2020118113A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4349414B1 (en) | 2014-12-23 | 2025-10-15 | Dyve Biosciences, Inc. | Formulations for transdermal administration |
| EP3484862B1 (en) | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| WO2020232156A1 (en) * | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| DE19624292A1 (de) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| WO2005121112A1 (ja) | 2004-06-10 | 2005-12-22 | Torii Pharmaceutical Co., Ltd. | ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| CN101765582A (zh) | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| US8791077B2 (en) | 2008-05-22 | 2014-07-29 | Astrazeneca Ab | Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same |
| JP5325065B2 (ja) | 2009-09-30 | 2013-10-23 | 株式会社富士薬品 | 新規フェノール誘導体 |
| IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| US10005750B2 (en) | 2010-10-06 | 2018-06-26 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
| US20150031768A1 (en) | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| US9060987B2 (en) | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| WO2014149789A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| WO2014194226A2 (en) | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| WO2015134467A1 (en) | 2014-03-05 | 2015-09-11 | The Trustees Of Princeton University | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks |
| CN107001356B (zh) | 2014-07-31 | 2019-09-03 | 默克专利有限公司 | 用于神经退化性疾病的中氮茚衍生物 |
| CN104262305B (zh) * | 2014-09-16 | 2016-06-08 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型a及其制备方法 |
| CN104311516B (zh) * | 2014-09-16 | 2017-01-11 | 东北制药集团股份有限公司 | 一种苯溴马隆晶型b及其制备方法 |
| EP3484862B1 (en) | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| KR101964435B1 (ko) | 2016-12-14 | 2019-04-01 | 주식회사 엘지화학 | 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| US20210130312A1 (en) | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2019233459A1 (zh) | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| MX2021003845A (es) | 2018-10-01 | 2021-05-27 | Astrazeneca Ab | Composiciones para reducir el acido urico serico. |
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| WO2020232156A1 (en) | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
| CN112079830B (zh) | 2019-06-14 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含并环类衍生物抑制剂、其制备方法和应用 |
| KR20230024354A (ko) | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| CN111763215B (zh) | 2020-07-21 | 2021-05-18 | 成都海博为药业有限公司 | 一种具有含氮杂环结构的化合物及其制备方法和用途 |
| CN112729156A (zh) | 2020-12-24 | 2021-04-30 | 上海智能制造功能平台有限公司 | 一种人体数字化测量装置的数据拼接及系统标定方法 |
| CN114697265A (zh) | 2020-12-29 | 2022-07-01 | 华为技术服务有限公司 | 一种报文处理方法及装置 |
| JP2024532249A (ja) | 2021-08-24 | 2024-09-05 | アースローシ セラピューティクス，インク． | 疾患の処置のためのキナゾリン化合物 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
-
2019
- 2019-12-05 KR KR1020217021172A patent/KR102946486B1/ko active Active
- 2019-12-05 EP EP19893127.1A patent/EP3890723A4/en active Pending
- 2019-12-05 WO PCT/US2019/064784 patent/WO2020118113A1/en not_active Ceased
- 2019-12-05 AU AU2019394974A patent/AU2019394974B2/en active Active
- 2019-12-05 SG SG11202105745UA patent/SG11202105745UA/en unknown
- 2019-12-05 EA EA202191545A patent/EA202191545A1/ru unknown
- 2019-12-05 JP JP2021531047A patent/JP2022511800A/ja active Pending
- 2019-12-05 US US17/311,249 patent/US12145917B2/en active Active
- 2019-12-05 CN CN201980080515.8A patent/CN113226302B/zh active Active
- 2019-12-05 IL IL283663A patent/IL283663B2/en unknown
- 2019-12-05 BR BR112021010708-8A patent/BR112021010708A2/pt unknown
- 2019-12-06 TW TW108144814A patent/TWI828817B/zh active
-
2024
- 2024-10-11 US US18/913,928 patent/US20250059150A1/en active Pending
- 2024-10-25 JP JP2024188449A patent/JP2025026857A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530565A5 (https=) | ||
| JP2023082086A5 (https=) | ||
| JPWO2020118113A5 (https=) | ||
| JP2018509457A5 (https=) | ||
| JP4142621B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| FI3880678T3 (fi) | P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja | |
| JP2018531982A5 (https=) | ||
| JP2010539237A5 (https=) | ||
| JPWO2020165646A5 (https=) | ||
| CN104011035A (zh) | 卡巴他赛的晶型和用于制备其的方法 | |
| JP2024095561A5 (https=) | ||
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2025102940A5 (https=) | ||
| JP2013520488A5 (https=) | ||
| JP2010514725A5 (https=) | ||
| JP2016510767A5 (https=) | ||
| JP2009544756A5 (https=) | ||
| CA3232656A1 (en) | Crystal form of imidazolinone derivative | |
| US6521642B2 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis | |
| EP2598147A1 (en) | N-methylformamide solvate of dasatinib | |
| JP2015531354A5 (https=) | ||
| JP2004530660A5 (https=) | ||
| JP2011515461A (ja) | 微小管形成阻害剤として有用なベンゾフェノンチアゾール誘導体及びその製造方法 | |
| CA2553345A1 (en) | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | |
| JP2020083892A5 (https=) |